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Newly-developed methods for estimation of in vivo binding to neurotransmitter receptors should 
enable the detection and quantification of physiologic or pathologic changes in receptor numbers. 
In the present study, both equilibrium and kinetic experimental strategies for in vivo muscarinic 
receptor determination were applied to the detection of receptor changes induced by chronic in- 
hibition of acetylcholinesterase in the rat. Following one week of treatment, in vitro receptor 
autoradiography utilizing [3H]scopolamine revealed significant losses of muscarinic binding in the 
cerebral cortex, hippocampus, striatum and in cranial nerve motor nuclei. The in vivo distribution 
of [3H]scopolamine, following infusion to approach equilibrium binding in the brain, revealed 
reductions in binding which paralleled the pattern and magnitude of changes detected in vitro. A 
simplified tracer kinetic estimation following bolus injection of the ligand also detected substantial 
reductions in forebrain muscarinic receptor binding. These results indicate the feasibility of de- 
tecting receptor changes underlying neuropathologic conditions in vivo, and suggest that either 
equilibrium or kinetic experimental approaches may be extended to clinical research applications 
with the use of positron or single-photon emission tomography. 
KEY WORDS: Scopolamine; in vivo binding, muscarinic receptor, PET (positron emission tomography); 
autoradiography. 
INTRODUC~ON 
New methods are being explored for their potential 
to allow noninvasive in vivo measurements of human 
brain neurotransmitter receptors, enzymes, or other li- 
gand binding sites (1). Cerebral radioligand distributions 
may be imaged with the use of positron emission to- 
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mography (PET) or single-photon emission computed 
tomography (SPECT), and may be employed for mea- 
surement of regional binding site densities with appro- 
priate combinations of tracer molecules and experimental 
designs. As an example, prior research in experimental 
animals has indicated the feasibility of imaging musca- 
rinic cholinergic receptor density on the basis of the dis- 
tribution of [3H]scopolamine in vivo (2-4). 
Labeled scopolamine demonstrates desirable prop- 
erties for in vivo studies including high specificity for 
binding to the muscarinic receptor, clear distinction of 
specific from nonspecific binding, and absence of la- 
beled nonvolatile metabolites in the brain (2). Volatile 
metabolites are observed in the brain following injection 
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of [N-methyPH]scopolamine, presumably originating from 
peripheral metabolism of the tracer. However, they are 
easily removed by drying and do not interfere with ac- 
curate quantification of brain ligand distribution. 
Two differing experimental protocols have each 
provided estimates of scopolamine binding in the intact 
rat brain. The first method employs equilibrium analysis 
following maintenance of a constant, saturating ligand 
concentration (2,3). This procedure results in a static 
regional distribution of ligand which corresponds to 
muscarinic receptor binding with minor contributions from 
the presence of nonspecific ligand binding and free li- 
gand in the tissue. The second method makes use of 
kinetic compartmental analysis following bolus injection 
of a tracer dose of [3H]scopolamine (4). In this instance, 
the time-courses of regional brain and arterial plasma 
tracer are required for estimation of receptor binding. 
These data may be collected at multiple time points from 
individual subjects with the use of PET. However, in 
experiments employing small animals, the data must be 
compiled from invasive measurements on groups of sub- 
jects killed at varying post-injection intervals. A simpli- 
fied approach to kinetic binding estimation which requires 
independent knowledge or measurement of the regional 
cerebral capillary permeability-surface area product for 
the tracer and of regional cerebral blood flow has been 
previously proposed (4). This method should allow bind- 
ing estimates from a single observation of ligand distri- 
bution at a relatively long post-injection interval, when 
contribution from nonspecific binding is negligible. 
An important aspect of development and evaluation 
of new radioligand methods is the ability to detect al- 
terations in receptor binding which might arise in ex- 
perimental applications. In the present studies, both the 
equilibrium and tracer kinetic experimental approaches 
to estimation of [3H]scopolamine binding are applied to 
measurements of receptor down-regulation following 
chronic inhibition of acetylcholinesterase. 
EXPERIMENTAL PROCEDURE 
Dntg Treatment. Chronic inhibition of acetylcholinesterase was 
achieved by daily i.m. injection of diisopropylfluorophosphate (DFP) 
suspended in olive oil. Male Sprague-Dawley rats weighing between 
180 and 200 g were treated according to the following dose schedule: 
1.5, 1.0, 1.0, 0.5, 0.5, and 0.5 Ixg DFP/kg on days 1 to 6 of treatment, 
respectively. Receptor binding experiments were performed 18 to 30 
hr following the last treatment. Acute blockade of muscarinic receptors 
was produced by i.v. injection of atropine sulfate, 50 mg/kg, 5 min 
prior to in vivo binding studies. 
Equilibrium Scopolamine Binding In Vivo. Equilibrium scopola- 
mine binding to the muscarinic receptor in vivo was determined as 
described previously (2,3). The method employed results in equip 
ibration of cerebral receptors with a saturating (approximately 20 IxM) 
arterial plasma concentration of ligand, permitting regional estimates 
of receptor numbers from individual subjects. In brief, a bolus fol- 
lowed by a continuous infusion of [3H]seopolamine (15 mCi/kg total 
dose) were administered i.v. to produce a constant arterial concentra- 
tion of tracer for 240 rain. At the.end Of the infusion, animals were 
killed and brains were frozen in crushed dry ice. 
Coronal 20 izm thick sections were prepared in a cryostat and 
mounted on microscope slides, Sets of three slides, each containing 
duplicate sections, were obtained at intervals throughout the brain. 
The first of each group was rapidly dessicated on a hotplate at 60 to 
70~ for determination of total in vivo binding. Sections on the sub- 
sequent two slides were thaw-mounted and allowed to dry at room 
temperature. One was used for determination of specific in vivo bind- 
ing by washing in phosphate-buffered saline containing EDTA (PBS: 
NaC1 - 124 raM, KC1 - 2.7 raM, NazHPO 4 - 7.7 mM, KHzPO 4 - 1.5 
raM, EDTA - 1 mM, pH 7,4) at 4~ twice for 5 min, followed by a 
brief dip in 4~ distilled I420 to remove excess salts and air drying. 
This procedure had been shown to reduce nonspecific binding without 
loss of specific binding in preliminary in vitro binding assays to intact 
tissue sections. The final slide in each group was processed for in vitro 
determination of muscarinic receptors by pre-washing in PBS for 5 
min, incubation in PBS containing a saturating concentration of 
[3H]sc0polamine (10 nM) for 30 min at 24~ followed by washing 
for 10 rain at 4~ and air drying. 
AutoradiogramS were generated by apposing the slide-mounted 
tissue to tritium-sensitive X-ray film (Ultrofilm-aH, LKB, Gaithers- 
burg, MD) for 14 days. Following film development, regional brain 
isotope concentrations were estimated by computer-assisted densito- 
metry (MCID system, Imaging Research, St. Catherines, Ontario, 
Canada). Film densities overlying brain tissue were compared with 
those from calibrated radioactive standards, allowing estimation of 
apparent tissue radioactivity (5). 
Kinetic Scopolamine Binding In Vivo. It has been proposed fol- 
lowing tracer kinetic studies that the distribution of [all]scopolamine 
at a long interval (time t = "r) following bolus i.v. injection is related 
to the regional availability of muscarinic receptors (ref 4, equation 31): 
[kaf(1 - e TM) I" 
C-r ('r) = [k3+f( 1 _e_rS/r ] o Ch(t)dt (1) 
where Cr and CA are the regional tissue and the arterial concentrations 
of ligand, f represents cerebral blood flow, PS represents the local 
cerebral capillary permeability-surface area product, and k3 represents 
the rate of ligand binding to the muscarinic receptor. The relationship 
between receptor availability and k3 is described by: 
k3 = kaR (2) 
where k, is the bimolecular receptor-ligand association rate constant 
and R represents the free tissue receptor concentration. 
This simplified calculation of receptor binding following bolus 
administration of trace doses of [3H]scopolamine was applied in ani- 
mals following chronic cholinesterase inhibition and following acute 
atropine treatment, the latter to verify the specificity of the simplified 
method to muscarinic receptor availability. 
Femoral arterial and venous catheters were inserted in rats under 
light diethyl ether anesthesia. Following a 2 hr recovery period, bind- 
ing studies were initiated by bolus i.v. injection of 100 ~Ci of 
[aH]scopolamine, and simultaneously beginning continuous arterial blood 
withdrawal into a heparinized 1 ml syringe at approximately 0.0067 
ml rain -1 using an infusion/withdrawal pump (Harvard Apparatus, 
South Natick, MA). The possibility of ex vivo metabolism of the 
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ligand in the blood sample was minimized by packing the withdrawal 
syringe in ice. At the end of a 90 rain distribution period, cerebral 
blood flow was determined by i.v. injection of 20 to 50 ~Ci of N,N,N',- 
trimethyl-N'-(2-hydroxy-3-methyl-5-[123I]iodobenzyl)-l,3-propanedi - 
amine ([123I]HIPDM) and simultaneous withdrawal of a second arterial 
blood sample at 0.21 ml rain -1 for 45 sec (6,7). Cardioplegia was 
then induced by i.v. injection of KC1, arterial sampling was discon- 
tinued, and animals were rapidly killed by decapitation. 
Brains were dissected, and samples of the cerebral cortex, hip- 
pocampus, striatum and cerebellum were weighed on an analytical 
balance and dispersed by sonication in 1 ml of ethanol. Samples were 
then evaporated to dryness under vacuum to remove volatile JH, and 
were reconstituted by addition of 1OO ~i of HzO prior to the addition 
of 200 ~t of a tissue solubilizer (Soluene-350, Packard Instruments, 
Downers Grove, IL). The ~231 content of the samples was determined 
in a gamma counter within 24 hr of the study. Sample 3H contenl was 
determined one week later, after decay of the ~z~I (t~/z = 13.3 h), by 
addition of 1.8 ml of scintillation fluid (ACS, Amersham, Arlington 
Hts., IL) followed by liquid scintillation spectroscopy. 
The integrated arterial concentration of [3H]scopolamine during 
the 90 rain distribution period was calculated from the volume of blood 
withdrawn (V), the time of withdrawal (,r), and the plasma concentra- 
tion of authentic ligand in the sample: 
f" o CA(t)dt = CA X V X 'r (3) 
where CA is the average concentration of unmetabolized [3H]scopolamine 
over the interval of observation, as may be determined from the con- 
tinuously-acquired blood sample. The nonvolatile 3H plasma activity 
was determined by scintillation counting of duplicate 10 ~1 samples 
following drying at 60~ The fraction of nonvolatile activity corre- 
sponding to unmetabolized [3H]scopolamine was determined in par- 
allel by thin-layer chromatography on silica gel with a tetrahydrofuran- 
diisopropylethylamine 95:5 mobile phase (2). 
Regional cerebral blood flow was calculated from the tissue and 
second blood sample concentrations of [;z3I]HIPDM using the indi- 
cator fractionation method (8) as described by Van Uitert and Levy 
(9): 
(Brain123I Activity) (Blood Withdrawal Rate) 
f = (4) (Blood 1231 Activity) 
The regional scopolamine binding rate k~ was determined from the 
tissue [3H]scopolamine content, the integrated plasma pH]scopolamine 
concentration (eq 3), and regional cerebral blood flow (eq 4), accord- 
ing to eq 1. The cerebral PS for scopolamine was assumed to be 0.12 
ml plasma/g brain/min as determined in prior studies (4). 
Materials. Labeled scopolamine was obtained by custom tritiation 
from Amersham (Arlington Hts., IL) and was adjusted to a specific 
activity of 30 Ci/mmol with unlabeled scopolamine. 
Radioiodonated HIPDM was produced by exchange labeling (6) 
with the use of [a23I]NaI obtained from Crocker Laboratories (Davis, 
CA). Atropine sulfate, scopolamine hydrochloride, and DFP were pur- 
chased from Sigma (St. Louis, MO). 
RESULTS 
Relationship of Equilibrium In Vivo Distribution to 
In Vitro Binding of [3H]Scopolamine. The autoradi- 
ographic results of total in vivo [3H]scopolamine binding 
were compared with those following ex vivo removal of 
unbound tracer (in vivo specific binding) and with in 
vitro [3H]~copolamine binding. As expected, brief wash- 
ing of the tissue following in vivo infusion of 
[3H]scopolamine reduced estimates of ligand binding in 
most brain regions. An unanticipated finding was that 
the apparent activity in brain regions with highest bind- 
ing (subregions CA1 and the dentate gyms of the hip- 
pocampal formation, striatum, and cerebral cortex) 
increased following washing (Figure 1). The relation- 
ships between in vivo tetaI or specific binding and in 
vitro [3H]scopolamine binding each support a predomi- 
nant effec~ of mu~earinic receptor concentration on in 
vivo accumulation of ligand under the equilibrium ex- 
perimental conditions, with a minor contribution from 
nonspecific binding and free ligand. 
Muscarinic Receptor Changes In Vilro Following 
Chronic Acetylcholinesterase Inhibition. Following one 
week of acetylcholinesterase inhibition by DFP, regional 
brain muscarinic receptor binding was significantly re- 
duced in several areas (Table I). Most affected were the 
cerebral cortex, the hippocampal formation, the stria- 
turn, the basolateral amygdala, and the nuclei of the 
facial and hypoglossal nerves. Other regions demon- 
strated only slight reduction or no change in binding with 
the exception of the substantia nigra pars reticulata, where 
a trend towards increased binding was observed. 
Detection of Receptor Changes by Equilibrium In 
Vivo [SH]Scopolamine Binding. As observed in in vitro 
autoradiographic assays, the equilibrium in vivo binding 
of [3H]scopolamine was significantly reduced in specific 
brain regions following DFP treatment. The reductions 
in total in vivo accumulation of scopolamine (Table II) 
were qualitatively similar to those in specific in vivo 
binding, following ex vivo washing of tissue sections 
(data not shown). The regional patterns and magnitudes 
of receptor changes were in good agreement between the 
equilibrium in vivo and the in vitro assays. : 
Effects of Chronic AcetyIcholinesterase inhibition 
and of Acute Atropine Treatment on Kinetic Receptor 
Binding Estimates. Regional cerebral blood flow was 
decreased approximately 15 to 35% by chronic admin- 
istration of DFP in all regions examined (~able III). 
Reductions in the k3 estimates for [3H]scopo!amine of 
approximately 50% were observed in the cerebral cortex, 
striatum, and hippocampus (Table IV). In the cerebel- 
Ium, kinetic binding estimates were reduced by com- 
parison to controls, however, the magnitude of the change 
was minor by comparison to the forebrain regions. Ce- 
rebral cortical kinetic binding estimates expressed rela- 
tive to the cerebellum reveal substantial reductions 
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Fig. 1. Comparisons of total and specific in vivo binding with in vitro 
binding of scopolamine. A. Total in vivo binding of [3H]scopolamine 
versus in vitro binding as determined by quantitative autoradiography 
from adjacent brain sections in 4 subjects (designated by n A, <>, 
and o). Apparent isotope concentrations for regions listed in Table I 
are plotted. The linear relationship between the measures for structures 
with in vitro binding less than 150 dpm/Ixg protein is given by the 
dashed line. B. Specific in vivo [3H]scopolamine binding versus in 
vitro binding as determined by quantitative autoradiography. Mea- 
surements are taken from autoradiograms of sections immediately ad- 
jacent to those used in A, following washing to reduce nonspecific 
binding. The linear relationship between the measures for structures 
with in vitro binding less than 200 dpm/Ixg protein is given by the 
dashed line. The relationship determined in A is plotted for comparison 
(solid line), Note the relative downward shift and increase in slope 
produced by ex vivo washing of the tissue sections. In addition, there 
is differential enhancement of apparent activity in structures with high- 
est receptor density, corresponding to the cerebral cortex, hippocam- 
pus, and striatum. 
grea te r  e f fec t  on  the  fo r eb ra in  r eg ions  t han  on  ce rebe l l a r  
b i n d i n g .  
A c u t e  admin i s t r a t i on  o f  a sa tu ra t ing  dose  of  atro-  
p ine  resu l ted  in smal l  inc reases  in C B F  and  large r educ-  
t ions  in m u s c a r i n i c  recep tor  b i n d i n g  es t ima tes ,  the  la t ter  
r a n g i n g  b e t w e e n  90 to 95% in the  fo r eb ra in  r eg ions  and  
over  7 5 %  in the  ce rebe l lum.  T h u s ,  m o s t  o f  the  k inet i -  
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Table L Effect of Chronic DFP Treatment on In Vitro Muscarinic 
Receptor Binding 
Brain Region Control DFP 
Frontal Cortex 2.08 -+ .07 1.54 • .052 
Striatum 2.54 • .13 1.67 • .082 
Hippocampus: CA1 3.24 • .41 2.68 • .08 
CA3 1.61 • .23 1.29 • .06 
Dentate Gyrus 2.61 • .23 2.05 _ .071 
Lateral Septal N. 1.16 --- .09 0.89 • .13 
Globus Pallidus 0.23 • .02 0.23 • .02 
Ventral Ant. Thalamus 0.61 • .06 0.60 • .03 
Corticomedial Amygdala 1.16 • .07 0.92 • .061 
Basolateral Amygdala 2.26 + .14 1.61 _ .072 
Ventral Post. Thalamus 0.94 - .04 0.86 • .03 
Lateral Geniculate 0.89 - .11 0.79 _ .04 
Medial Geniculate 0.83 • .09 0.76 ___ .11 
Substantia Nigra R. 0.50 • .05 0.61 -4- .071 
Periaqueductal Gray 0.95 • .07 0.82 • .04 
Basal Pontine Nuclei 1.78 • .17 1.60 • .18 
Cerebellar Cortex 0.17 • .05 0.15 • .02 
Facial Nucleus 1.15 • .063 0.90 • .17 
Hypoglossal Nucleus 1.91 • .093 0.84 - .142 
Values represent the mean _+ SD of observations from four 
in each group, expressed in fmol/Ixg protein. 
lp<0.05 by Student's t test. 
Zp<0.001 by Student's t test. 
3n = 3 subjects. 
subjects 
Table IL Effect of Chronic DFP Treatment on Equilibrium 
[3H]Scopolamine Binding In Vivo 
Brain Region Control DFP 
Frontal Cortex 1.85 - .07 1.41 ___ .062 
Striatum 2.08 • .11 1.57 _ .091 
Hippocampus: CA1 2.02 - .20 1.85 _+ .25 
CA3 1.59 - .20 1.28 _ .07 
Dentate Gyrus 2.03 --- .19 1.70 • .07 
Lateral Septal N. 1.27 --- .08 1.15 _ .07 
Globus Pallidus 0.37 • .02 0.38 • .04 
Ventral Ant. Thalamus 0.81 - .06 0.84 ___ .05 
Corticomedial Amygdala 1.19 • .09 0.99 + .011 
Basolateral Amygdala 1.91 --- .06 1.42 • .022 
Ventral Post. Thalamus 1.07 • .07 0.99 • .06 
Lateral Geniculate 0.97 • .11 0.92 • .04 
Medial Geniculate 0.95 • .13 0.88 _ .08 
Substantia Nigra R. 0.60 • .03 0.73 --_ .071 
Periaqueductal Gray 0.98 • .10 0.92 • .07 
Basal Pontine Nuclei 1.85 • .18 1.86 _+ .05 
Cerebellar Cortex 0.29 • .06 0.31 • .03 
Facial Nucleus 1.21 • .033 1.02 • .17 
Hypoglossal Nucleus 1.57 • .093 0.98 • .082 
Values represent the mean • SD of observations from 
in each group, expressed in fmol/~g protein. 
lp<0.05 by Student's t test. 
2p<0.001 by Student's t test. 
3n = 3 subjects. 
four subjects 
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Table III. Effects of Chronic DFP and of Acute Atropine 
Treatments on Regional Cerebral Blood Flow 
Brain Region Control DFP Atropine 
(n=6)  (n=3)  (n=3)  
Frontal Cortex 1.1 _+ .3 0.7--- .1 1.2+ .1 
Striatum 0.9_+.2 0.6 +.11 1 . 2 - . 1  
Hippocampus 0.7 •  1 0.5 •  11 0.7 •  1 
Cerebellum 0.8 • .1 0.5 - .1 1.1 • .2 
Values represent the mean _+ s.I). of regional cerebral blood flow 
determinations expressed as ml blood/g brain/min. 
lp < 0.05 versus control by pairwise Scheffe tests, following significant 
(p < 0.05) one-way ANOVA. 
cally-estimated ligand binding in the control and DFP- 
treated groups is attributable to muscarinic receptor 
availability. 
DISCUSSION 
Relationship of In Vivo and In Vitro Equilibrium 
Receptor Binding. The present study extends prior ob- 
servations on the equilibrium binding application of la- 
beled scopolamine for measurement of cerebral muscarinic 
receptor availability in vivo. It has been previously de- 
termined that the relationship between total scopolamine 
binding in vivo and in vitro estimates of muscarinic re- 
ceptors made with [3H]quinuclidinyl benzilate are highly 
correlated, and that there is a component suggestive of 
the presence of nonspecific binding and free ligand under 
in vivo conditions (2,3). In the present studies, this spec- 
ulation has been confirmed following ex vivo washing 
of tissue to reduce the contribution of nonspecific bind- 
ing. Following washing, the relationship between in vivo 
and in vitro binding is linear with an intercept at the 
origin. 
1021 
An unexpected additional finding in these studies 
is the apparent increase in ligand concentration following 
washing of the tissue, particularly evident in brain re- 
gions with greatest receptor densities. Several of these 
regions appear to deviate from the linear relationship 
between total binding in vivo and in vitro determined 
for regions of low to moderate receptor concentration. 
The apparent underestimation of in vivo binding in these 
regions is not due to failure to fully equilibrate ligand 
binding, the presence of endogenous neurotransmitter, 
or other factors affecting the biodistribution of tracer, 
since post-washing of the labeled tissue restores linear 
correlation of the in vivo and in vitro binding estimates 
in these regions. It is unlikely that unbound tracer from 
distant regions is removed and then rebound to account 
for these changes, since the washing procedure was con- 
ducted in relatively large volumes of buffer (greater than 
10 ml per slide in each of two 5 rain washes) and was 
conducted at 4~ An alternative is suggested by in- 
spection of the linear regression slopes in the pre- and 
post-washing conditions. An increase in the slope relat- 
ing in vivo to in vitro binding is seen even in the regions 
of low receptor concentration. In addition, the regression 
slope in the in vivo specific binding case is less than 
unity, suggesting that incubation of tissue for 30 min at 
24~ produces an incremental effect. These observations 
suggest that incubation in buffer alters the self-absorp- 
tion properties of the tissue sections, perhaps by elimi- 
nation of salts, soluble proteins, or other attenuating 
factors. The differential effects noted in the cerebral cor- 
tex and hippocampal formation may be due to concen- 
tration of binding sites in subregions (lamina) with greatest 
loss of attenuating factors. Tissue attenuation effects on 
autoradiographic quantification of tritium have been pre- 
viously documented in relation to regional differences in 
brain lipid content (10-12). The effect suggested by the 
present studies cannot be investigated in exclusively in 
Table IV. Effects of Chronic DFP and of Acute Atropine Treatments on Tracer Kinetic Estimates of [all]Scopolamine Binding In Vivo 
Binding Relative to Cerebellum 1 
Brain Region Control DFP Atropine Control DFP Atropine 
(n = 6) (n = 3) (n = 3) (n = 6) (n = 3) (n = 3) 
Frontal Cortex 0.14 + .05 0.05 + .012 0 .007-  .0043 4.3 __ 1.0 2.3 + 0.32 1.1 + .032 
Striatum 0.09 • .04 0.04 • .01 0.007 -- .0052 2.7 +_ 0.9 1.7 +2_ 0.1 1.0 • 0.42 
Hippocampus 0.08 + .02 0.04 • .012 0.008 • .0063 2.4 • 0.3 2. i + 0.2 1.2-+ 0.33 
Cerebellum 0.03 • .01 0.02 ~ .012 0.007 • .0043 
Values represent the mean • SD of kinetic binding estimates. 
~Regional values expressed relative to the cerebellum from the corresponding subject. 
2p < 0.05 by pairwise Scheffe test, following significant (p <0.05) one-way ANOVA. 
3p<0.01 by pairwise Scbeffe test, following significant (p<0.05) one-way ANOVA. 
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vitro studies, since in vivo labeling of the tissue is nec- 
essary for its detection. Thus, an additional caveat in 
interpretation of in vitro autoradiographic receptor de- 
terminations with tritiated ligands is suggested. The ef- 
fect may contribute to minor differences in apparent 
receptor distribution between autoradiographic and tis- 
sue homogenate binding studies. 
Effect of Chronic Acetylcholinesterase Inhibition on 
Muscarinic Receptors. The current studies are in good 
agreement with prior observations of reduced muscarinic 
receptors in the rat brain following inhibition of acetyl- 
cholinesterase. Treatment with DFP causes reduction in 
striatal (13) and in cortical (14) muscarinic receptors as 
quantified in homogenate binding assays. A prior study 
utilizing semi-quantitative tissue autoradiography fol- 
lowing DFP treatment (15) found reductions in cerebral 
cortical, striatal, and hippocampal binding as in the pres- 
ent work. The prior results, however, suggest reductions 
in septal and pontine binding not evident in the present 
study. The reduction in hypoglossal nucleus and the small 
increase in substantia nigra receptor binding observed in 
the present work have not been previously reported. The 
reason for these discrepancies is uncertain, but may re- 
side in differences in DFP administration schedules or 
in the methodology for quantification of autoradi- 
ographic binding. Nevertheless, the major findings of 
the investigations are in agreement that DFP treatment 
produces a loss of muscarinic receptor binding in fore- 
brain areas with high densities of presynaptic cholinergic 
terminals. It is likely that this effect is indirectly me- 
diated by increases in acetylcholine levels, since prior 
lesioning of presynaptic cholinergic terminals prevents 
neocortical receptor losses (14). 
Comparison of Equilibrium and Tracer Kinetic 
Binding Methods. Results from both equilibrium and ki- 
netic in vivo binding studies indicate the feasibility of 
detecting altered receptor populations. By comparison 
with the results of in vitro binding, neither in vivo method 
appears as sensitive, due to variability in the data. The 
equilibrium method results in better precision than the 
kinetic method, however, this may be partly attributed 
to differences in region identification and tissue sam- 
pling which tend to favor the autoradiographic equilib- 
rium binding design. In addition, the kinetic calculation 
applied here may suffer from invalid assumptions con- 
cerning ligand transport. First, the determination of ce- 
rebral blood flow was made at the end of the 90 min 
[3H]scopolamine distribution period. Since effects of flow 
on ligand transport and binding are greatest immediately 
following bolus injection, changes in perfusion during 
the course of the experiment might lead to inaccurate 
correction for ligand transport. Second, and more sig- 
nificantly, since scopolamine transport is highly sensi- 
tive to PS, it may be incorrect to assume a constant value 
across experimental groups. A combination of these er- 
rors may underlie apparent loss of binding in the cere- 
bellum in kinetic studies. It has been previously reported 
that PS varies in the same direction as cerebral blood 
flow during alterations in arterial pCOz and following 
administration of antidepressants (16-18). Thus, PS may 
have been lower than assumed in the DFP-treated ani- 
mals, leading to underestimation of binding in the kinetic 
experiments. This error alone may be sufficient to ac- 
count for the small reduction in cerebellar binding, and 
may contribute to the greater magnitude of forebrain re- 
ceptor losses in the kinetic as compared to the equilib- 
rium experiments. On the basis of method precision and 
due to the considerations above, the equilibrium in vivo 
[3H]scopolamine binding method would appear most fa- 
vorable for studies in experimental animals. 
Implications for Clinical Receptor Imaging Studies. 
Clinical research quantification of muscarinic receptors 
may, in theory, be accomplished by application of PET 
imaging to the detection of scopolamine labeled with the 
positron emitting nuclide 11C ([11C]scopolamine; 19,20). 
On the basis of the foregoing comparison in experimen- 
tal animals, the equilibrium approach might appear de- 
sirable for clinical measures as well. However, equilibrium 
imaging with labeled scopolamine requires saturating li- 
gand levels over a several hour period. Both of these 
conditions are unobtainable due to the adverse clinical 
effects of high doses of scopolamine and to the short (20 
min) isotopic half-life of 11C. The tracer kinetic exper- 
imental design is thus the only available choice for such 
studies, and might yield results more precise than pre- 
dicted by the current studies. The entire brain time-course 
of tracer activity may be obtained by dynamic PET im- 
aging, eliminating the need for simplifying assumptions 
about initial ligand extraction, PS, and CBF. Thus, the 
physiologic accuracy and precision of clinical kinetic 
measures may exceed estimates derived from the current 
animal studies. In fact, measurements of muscarinic re- 
ceptor binding with the kinetic [l~C]scopolamine method 
have been achieved with PET in normal human volun- 
teers (21). The present studies suggest the feasibility of 
detecting alterations in cortical and perhaps other re- 
gional receptor populations with this method. 
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